Cortical beta amyloid protein triggers an immune response, but no synaptic changes in the APPswe/PS1dE9 Alzheimer's disease mouse model

Neurobiology of Aging

Volumn 34, Issue 5, 2013, Pages 1328-1342

  Wirz, Kerstin T S ^a   Bossers, Koen ^a   Stargardt, Anita ^a   Kamphuis, Willem ^a   Swaab, Dick F ^a   Hol, Elly M ^a,b   Verhaagen, Joost ^a,c  

^a NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Alzheimer's disease; APPswe PS1dE9 mice; Beta amyloid protein; Immune response; Microarray; Synaptic activity and plasticity

Indexed keywords

ACTIVITY REGULATED CYTOSKELETON ASSOCIATED PROTEIN; ALLOGRAFT INFLAMMATORY FACTOR 1; AMYLOID BETA PROTEIN; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 1; APOLIPOPROTEIN C4; CATHEPSIN; CHEMOKINE; CHOLESTEROL 25 HYDROXYLASE; COMPLEMENT; COMPLEMENT COMPONENT C4B; DIFFERENTIATION ANTIGEN; EARLY GROWTH RESPONSE FACTOR 1; GLIAL FIBRILLARY ACIDIC PROTEIN; LIPOPROTEIN LIPASE; MESSENGER RNA; NUCLEAR RECEPTOR NUR77; PLEXIN; PROTEOLIPID PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; COMPLEMENT COMPONENT 4B GENE; CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; GENE CLUSTER; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GLIA CELL; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNE RESPONSE GENE; IMMUNOREGULATION; LIPID METABOLISM; MALE; MEMORY; MOUSE; NERVE CELL PLASTICITY; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PLEXIN DOMAIN CONTAINING 2 GENE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN FUNCTION; SOLUTE CARRIER FAMILY 14 UREA TRANSPORTER MEMBER 1 GENE; SYNAPTIC TRANSMISSION; TRANSCRIPTION REGULATION; UNINDEXED SEQUENCE; UPREGULATION;

AGING; ALZHEIMER DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; FRONTAL LOBE; HUMANS; IMMUNITY, INNATE; MICE; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NEURONAL PLASTICITY; SYNAPTIC TRANSMISSION;

EID: 84873428541     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.11.008     Document Type: Article

References (102)

1. Agrawal S., Kishore M.C. MHC class I gene expression and regulation. J. Hematother. Stem Cell Res. 2000, 9:795-812.
2. Arnaud L., Robakis N.K., Figueiredo-Pereira M.E. It may take inflammation, phosphorylation and ubiquitination to " tangle" in Alzheimer's disease. Neurodegener. Dis. 2006, 3:313-319.
3. Arvat E., Broglio F., Ghigo E. Insulin-Like growth factor I: implications in aging. Drugs Aging 2000, 16:29-40.
4. Bagnasco S.M. The erythrocyte urea transporter UT-B. J. Membr. Biol. 2006, 212:133-138.
5. Beißbarth T., Speed T.P. GOstat: find statistically overrepresented Gene Ontologies within a group of genes. Bioinformatics 2004, 20:1464-1465.
6. Belfort G.M., Kandror K.V. Cellugyrin and synaptogyrin facilitate targeting of synaptophysin to a ubiquitous synaptic vesicle-sized compartment in PC12 cells. J. Biol. Chem. 2003, 278:47971-47978.
7. Bertram L., Tanzi R.E. The genetic epidemiology of neurodegenerative disease. J. Clin. Invest. 2005, 115:1449-1457.
8. Blalock E.M., Geddes J.W., Chen K.C., Porter N.M., Markesbery W.R., Landfield P.W. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc. Natl. Acad. Sci. U. S. A 2004, 101:2173-2178.
9. Blasko I., Marx F., Steiner E., Hartmann T., Grubeck-Loebenstein B. TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. FASEB J. 1999, 13:63-68.
10. Boissonneault V., Filali M., Lessard M., Relton J., Wong G., Rivest S. Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease. Brain 2009, 132:1078-1092.
11. Bonardi C., de Pulford F., Jennings D., Pardon M.-C. A detailed analysis of the early context extinction deficits seen in APPswe/PS1dE9 female mice and their relevance to preclinical Alzheimer's disease. Behav. Brain Res. 2011, 222:89-97.
12. Bornemann K.D., Wiederhold K.H., Pauli C., Ermini F., Stalder M., Schnell L., Sommer B., Jucker M., Staufenbiel M. Abeta-induced inflammatory processes in microglia cells of APP23 transgenic mice. Am. J. Pathol. 2001, 158:63-73.
13. Bossers K., Wirz K.T.S., Meerhoff G.F., Essing A.H.W., van Dongen J.W., Houba P., Kruse C.G., Verhaagen J., Swaab D.F. Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease. Brain 2010, 133:3699-3723.
14. Bossers K., Ylstra B., Brakenhoff R.H., Smeets S.J., Verhaagen J., van de Wiel M.A. Intensity-based analysis of dual-color gene expression data as an alternative to ratio-based analysis to enhance reproducibility. BMC Genomics 2010, 11:112.
15. Braak H., de Vos R.A., Jansen E.N., Bratzke H., Braak E. Neuropathological hallmarks of Alzheimer's and Parkinson's diseases. Prog. Brain Res. 1998, 117:267-285.
16. Cahoy J.D., Emery B., Kaushal A., Foo L.C., Zamanian J.L., Christopherson K.S., Xing Y., Lubischer J.L., Krieg P.A., Krupenko S.A., Thompson W.J., Barres B.A. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J. Neurosci. 2008, 28:264-278.
17. Carro E., Trejo J.L., Gerber A., Loetscher H., Torrado J., Metzger F., Torres-Aleman I. Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis. Neurobiol. Aging 2006, 27:1250-1257.
18. Carson-Walter E.B., Watkins D.N., Nanda A., Vogelstein B., Kinzler K.W., St Croix B. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res. 2001, 61:6649-6655.
19. Chen K., Iribarren P., Hu J., Chen J., Gong W., Cho E.H., Lockett S., Dunlop N.M., Wang J.M. Activation of Toll-like receptor 2 on microglia promotes cell uptake of Alzheimer disease-associated amyloid beta peptide. J. Biol. Chem. 2006, 281:3651-3659.
20. Davies G., Cunnick G.H., Mansel R.E., Mason M.D., Jiang W.G. Levels of expression of endothelial markers specific to tumour-associated endothelial cells and their correlation with prognosis in patients with breast cancer. Clin. Exp. Metastasis. 2004, 21:31-37.
21. DeKosky S.T., Aston C.E., Kamboh M.I. Polygenic determinants of Alzheimer's disease: modulation of the risk by alpha-1-antichymotrypsin. Ann. N. Y. Acad. Sci. 1996, 802:27-34.
22. Dickey C.A., Gordon M.N., Mason J.E., Wilson N.J., Diamond D.M., Guzowski J.F., Morgan D. Amyloid suppresses induction of genes critical for memory consolidation in APP + PS1 transgenic mice. J. Neurochem. 2004, 88:434-442.
23. Dickey C.A., Loring J.F., Montgomery J., Gordon M.N., Eastman P.S., Morgan D. Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. J. Neurosci. 2003, 23:5219-5226.
24. Duan R.S., Yang X., Chen Z.G., Lu M.O., Morris C., Winblad B., Zhu J. Decreased fractalkine and increased IP-10 expression in aged brain of APP(swe) transgenic mice. Neurochem. Res. 2008, 33:1085-1089.
25. Eikelenboom P., van Exel E., Hoozemans J.J.M., Veerhuis R., Rozemuller A.J.M., van Gool W.A. Neuroinflammation - an early event in both the history and pathogenesis of Alzheimer's disease. Neurodegener. Dis. 2010, 7:38-41.
26. Eikelenboom P., Veerhuis R., van Exel E., Hoozemans J.J.M., Rozemuller A.J.M., van Gool W.A. The early involvement of the innate immunity in the pathogenesis of late-onset Alzheimer's disease: neuropathological, epidemiological and genetic evidence. Curr. Alzheimer Res. 2011, 8:142-150.
27. Emilsson L., Saetre P., Jazin E. Alzheimer's disease: mRNA expression profiles of multiple patients show alterations of genes involved with calcium signaling. Neurobiol. Dis. 2006, 21:618-625.
28. Fan R., Xu F., Previti M.L., Davis J., Grande A.M., Robinson J.K., Van Nostrand W.E. Minocycline reduces microglial activation and improves behavioral deficits in a transgenic model of cerebral microvascular amyloid. J. Neurosci. 2007, 27:3057-3063.
29. Filali M., Lalonde R. Age-related cognitive decline and nesting behavior in an APPswe/PS1 bigenic model of Alzheimer's disease. Brain Res. 2009, 1292:93-99.
30. Fonseca M.I., Chu S.H., Berci A.M., Benoit M.E., Peters D.G., Kimura Y., Tenner A.J. Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer's disease. J. Neuroinflammation 2011, 8:4.
31. Frank S., Burbach G.J., Bonin M., Walter M., Streit W., Bechmann I., Deller T. TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia 2008, 56:1438-1447.
32. Frank-Cannon T.C., Alto L.T., McAlpine F.E., Tansey M.G. Does neuroinflammation fan the flame in neurodegenerative diseases?. Mol. Neurodegener. 2009, 4:47.
33. Frankola K.A., Greig N.H., Luo W., Tweedie D. Targeting TNF-α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases. CNS Neurol. Disord. Drug Targets 2011, 10:391-403.
34. Galimberti D., Schoonenboom N., Scheltens P., Fenoglio C., Bouwman F., Venturelli E., Guidi I., Blankenstein M.A., Bresolin N., Scarpini E. Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch. Neurol. 2006, 63:538-543.
35. Garcia-Alloza M., Robbins E.M., Zhang-Nunes S.X., Purcell S.M., Betensky R.A., Raju S., Prada C., Greenberg S.M., Bacskai B.J., Frosch M.P. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol. Dis. 2006, 24:516-524.
36. Gasparini L., Xu H. Potential roles of insulin and IGF-1 in Alzheimer's disease. Trends Neurosci. 2003, 26:404-406.
37. Gilchrist M., Thorsson V., Li B., Rust A.G., Korb M., Roach J.C., Kennedy K., Hai T., Bolouri H., Aderem A. Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4. Nature 2006, 441:173-178.
38. Gimbel D.A., Nygaard H.B., Coffey E.E., Gunther E.C., Lauren J., Gimbel Z.A., Strittmatter S.M. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J. Neurosci. 2010, 30:6367-6374.
39. Hanisch U.K., Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 2007, 10:1387-1394.
40. Harvey R.J., Skelton-Robinson M., Rossor M.N. The prevalence and causes of dementia in people under the age of 65 years. J. Neurol. Neurosurg. Psychiatr. 2003, 74:1206-1209.
41. Hickman S.E., Allison E.K., El K.J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J. Neurosci. 2008, 28:8354-8360.
42. Holcomb L., Gordon M.N., McGowan E., Yu X., Benkovic S., Jantzen P., Wright K., Saad I., Mueller R., Morgan D., Sanders S., Zehr C., O'Campo K., Hardy J., Prada C.M., Eckman C., Younkin S., Hsiao K., Duff K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 1998, 4:97-100.
43. Hooijmans C.R., Van der Zee C.E.E.M., Dederen P.J., Brouwer K.M., Reijmer Y.D., van Groen T., Broersen L.M., Lütjohann D., Heerschap A., Kiliaan A.J. DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APPswe/PS1dE9 mice. Neurobiol. Dis. 2009, 33:482-498.
44. Israelsson C., Bengtsson H., Lobell A., Nilsson L.N.G., Kylberg A., Isaksson M., Wootz H., Lannfelt L., Kullander K., Hillered L., Ebendal T. Appearance of Cxcl10-expressing cell clusters is common for traumatic brain injury and neurodegenerative disorders. Eur. J. Neurosci. 2010, 31:852-863.
45. Jankowsky J.L., Fadale D.J., Anderson J., Xu G.M., Gonzales V., Jenkins N.A., Copeland N.G., Lee M.K., Younkin L.H., Wagner S.L., Younkin S.G., Borchelt D.R. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 2004, 13:159-170.
46. Jankowsky J.L., Melnikova T., Fadale D.J., Xu G.M., Slunt H.H., Gonzales V., Younkin L.H., Younkin S.G., Borchelt D.R., Savonenko A.V. Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer's disease. J. Neurosci. 2005, 25:5217-5224.
47. Janz R., Südhof T.C., Hammer R.E., Unni V., Siegelbaum S.A., Bolshakov V.Y. Essential roles in synaptic plasticity for synaptogyrin I and synaptophysin I. Neuron 1999, 24:687-700.
48. Jarvis K., Assis-Nascimento P., Mudd L.M., Montague J.R. Beta-amyloid toxicity and reversal in embryonic rat septal neurons. Neurosci. Lett. 2007, 423:184-188.
49. Johnston H., Boutin H., Allan S.M. Assessing the contribution of inflammation in models of Alzheimer's disease. Biochem. Soc. Trans. 2011, 39:886-890.
50. Kamboh M.I., Minster R.L., Kenney M., Ozturk A., Desai P.P., Kammerer C.M., DeKosky S.T. Alpha-1-antichymotrypsin (ACT or SERPINA3) polymorphism may affect age-at-onset and disease duration of Alzheimer's disease. Neurobiol. Aging 2006, 27:1435-1439.
51. Kamboh M.I., Sanghera D.K., Ferrell R.E., DeKosky S.T. APOE*4-associated Alzheimer's disease risk is modified by alpha 1-antichymotrypsin polymorphism. Nat. Genet. 1995, 10:486-488.
52. Kamphuis W., Orre M., Kooijman L., Dahmen M., Hol E.M. Differential cell proliferation in the cortex of the APPswePS1dE9 Alzheimer's disease mouse model. Glia 2012, 60:615-629.
53. Kedra D., Pan H.Q., Seroussi E., Fransson I., Guilbaud C., Collins J.E., Dunham I., Blennow E., Roe B.A., Piehl F., Dumanski J.P. Characterization of the human synaptogyrin gene family. Hum. Genet. 1998, 103:131-141.
54. Khuu C.H., Barrozo R.M., Hai T., Weinstein S.L. Activating transcription factor 3 (ATF3) represses the expression of CCL4 in murine macrophages. Mol. Immunol. 2007, 44:1598-1605.
55. Kilgore M., Miller C.A., Fass D.M., Hennig K.M., Haggarty S.J., Sweatt J.D., Rumbaugh G. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 2010, 35:870-880.
56. Labrousse V.F., Nadjar A., Joffre C., Costes L., Aubert A., Grégoire S., Bretillon L., Layé S. Short-term long chain omega3 diet protects from neuroinflammatory processes and memory impairment in aged mice. PLoS One 2012, 7:e36861.
57. Lagadec S., Rotureau L., Hémar A., Macrez N., Delcasso S., Jeantet Y., Cho Y.H. Early temporal short-term memory deficits in double transgenic APP/PS1 mice. Neurobiol. Aging 2012, 33. 203.e1-11.
58. Li C., Zhao R., Gao K., Wei Z., Yin M.Y., Lau L.T., Chui D., Hoi Yu A.C. Astrocytes: implications for neuroinflammatory pathogenesis of Alzheimer's disease. Curr. Alzheimer Res. 2011, 8:67-80.
59. Liang W.S., Dunckley T., Beach T.G., Grover A., Mastroeni D., Ramsey K., Caselli R.J., Kukull W.A., McKeel D., Morris J.C., Hulette C.M., Schmechel D., Reiman E.M., Rogers J., Stephan D.A. Neuronal gene expression in non-demented individuals with intermediate Alzheimer's Disease neuropathology. Neurobiol. Aging 2010, 31:549-566.
60. Liu S., Liu Y., Hao W., Wolf L., Kiliaan A.J., Penke B., Rübe C.E., Walter J., Heneka M.T., Hartmann T., Menger M.D., Fassbender K. TLR2 is a primary receptor for Alzheimer's amyloid β peptide to trigger neuroinflammatory activation. J. Immunol. 2012, 188:1098-1107.
61. Maier M., Peng Y., Jiang L., Seabrook T.J., Carroll M.C., Lemere C.A. Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J. Neurosci. 2008, 28:6333-6341.
62. Melchior B., Garcia A.E., Hsiung B.-K., Lo K.M., Doose J.M., Thrash J.C., Stalder A.K., Staufenbiel M., Neumann H., Carson M.J. Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic mice: implications for vaccine-based therapies for Alzheimer's disease. ASN Neuro. 2010, 2:e00037.
63. Melnikova T., Savonenko A., Wang Q., Liang X., Hand T., Wu L., Kaufmann W.E., Vehmas A., Andreasson K.I. Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern. Neuroscience 2006, 141:1149-1162.
64. Miller-Delaney S.F.C., Lieberam I., Murphy P., Mitchell K.J. Plxdc2 is a mitogen for neural progenitors. PLoS One 2011, 6:e14565.
65. Minkeviciene R., Ihalainen J., Malm T., Matilainen O., Keksa-Goldsteine V., Goldsteins G., Iivonen H., Leguit N., Glennon J., Koistinaho J., Banerjee P., Tanila H. Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-type mice. J. Neurochem. 2008, 105:584-594.
66. Mustafa A., Lannfelt L., Lilius L., Islam A., Winblad B., Adem A. Decreased plasma insulin-like growth factor-I level in familial Alzheimer's disease patients carrying the Swedish APP 670/671 mutation. Dement. Geriatr. Cogn. Disord. 1999, 10:446-451.
67. Olabarria M., Noristani H.N., Verkhratsky A., Rodríguez J.J. Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer's disease. Glia 2010, 58:831-838.
68. O'Leary T.P., Brown R.E. Visuo-spatial learning and memory deficits on the Barnes maze in the 16-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease. Behav. Brain Res. 2009, 201:120-127.
69. Parachikova A., Agadjanyan M.G., Cribbs D.H., Blurton-Jones M., Perreau V., Rogers J., Beach T.G., Cotman C.W. Inflammatory changes parallel the early stages of Alzheimer disease. Neurobiol. Aging 2007, 28:1821-1833.
70. Parachikova A., Cotman C.W. Reduced CXCL12/CXCR4 results in impaired learning and is downregulated in a mouse model of Alzheimer disease. Neurobiol. Dis. 2007, 28:143-153.
71. Park K.M., Bowers W.J. Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Cell Signal. 2010, 22:977-983.
72. Paul E., Pozdnyakova O.O., Mitchell E., Carroll M.C. Anti-DNA autoreactivity in C4-deficient mice. Eur. J. Immunol. 2002, 32:2672-2679.
73. Pillay N.S., Kellaway L.A., Kotwal G.J. Early detection of memory deficits and memory improvement with vaccinia virus complement control protein in an Alzheimer's disease model. Behav. Brain Res. 2008, 192:173-177.
74. Reddy P.H., McWeeney S., Park B.S., Manczak M., Gutala R.V., Partovi D., Jung Y., Yau V., Searles R., Mori M., Quinn J. Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. Hum. Mol. Genet. 2004, 13:1225-1240.
75. Richard K.L., Filali M., Préfontaine P., Rivest S. Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer's disease. J. Neurosci. 2008, 28:5784-5793.
76. Rmali K.A., Puntis M.C.A., Jiang W.G. Tumour-associated angiogenesis in human colorectal cancer. Colorectal Dis. 2007, 9:3-14.
77. Rolls A., Shechter R., London A., Ziv Y., Ronen A., Levy R., Schwartz M. Toll-like receptors modulate adult hippocampal neurogenesis. Nat. Cell Biol. 2007, 9:1081-1088.
78. Rozen S., Skaletsky H.J. Primer3 on the WWW for general users and for biologist programmers. Bioinformatics Methods and Protocols: Methods in Molecular Biology 2000, 365-386. Humana Press, Totowa, NJ. S. Krawetz, S. Misener (Eds.).
79. Ruan L., Kang Z., Pei G., Le Y. Amyloid deposition and inflammation in Appswe/Ps1de9 mouse model of Alzheimer's disease. Curr. Alzheimer Res. 2009, 6:531-540.
80. Sabroe I., Dower S.K., Whyte M.K.B. The role of Toll-like receptors in the regulation of neutrophil migration, activation, and apoptosis. Clin. Infect. Dis. 2005, 41(suppl 7):S421-S426.
81. Savonenko A., Xu G.M., Melnikova T., Morton J.L., Gonzales V., Wong M.P., Price D.L., Tang F., Markowska A.L., Borchelt D.R. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol. Dis. 2005, 18:602-617.
82. Selwood S.P., Parvathy S., Cordell B., Ryan H.S., Oshidari F., Vincent V., Yesavage J., Lazzeroni L.C., Murphy G.M. Gene expression profile of the PDAPP mouse model for Alzheimer's disease with and without apolipoprotein E. Neurobiol. Aging 2009, 30:574-590.
83. Smith K.G.C., Clatworthy M.R. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat. Rev. Immunol. 2010, 10:328-343.
84. Smyth G.K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 2004, 3. Article3.
85. Standiford T.J., Kuick R., Bhan U., Chen J., Newstead M., Keshamouni V.G. TGF-β-induced IRAK-M expression in tumor-associated macrophages regulates lung tumor growth. Oncogene 2011, 30:2475-2484.
86. Sugita S., Janz R., Südhof T.C. Synaptogyrins regulate Ca2+-dependent exocytosis in PC12 cells. J. Biol. Chem. 1999, 274:18893-18901.
87. Thomas D.M., Francescutti-Verbeem D.M., Kuhn D.M. Gene expression profile of activated microglia under conditions associated with dopamine neuronal damage. FASEB J. 2006, 20:515-517.
88. Timmer N.M., van D.L., Van der Zee C.E., Kiliaan A., De Waal R.M., Verbeek M.M. Enoxaparin treatment administered at both early and late stages of amyloid beta deposition improves cognition of APPswe/PS1dE9 mice with differential effects on brain A beta levels. Neurobiol. Dis. 2010, 40:340-347.
89. Toledo E.M., Inestrosa N.C. Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease. Mol. Psychiatry. 2010, 15:272-285. 228.
90. Torres-Aleman I. Serum growth factors and neuroprotective surveillance: focus on IGF-1. Mol. Neurobiol. 2000, 21:153-160.
91. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002, 3. RESEARCH0034.
92. Wisniewski T., Sigurdsson E.M. Murine models of Alzheimer's disease and their use in developing immunotherapies. Biochim. Biophys. Acta. 2010, 1802:847-859.
93. World Health Organization, Alzheimer's Disease International, 2012. Dementia: a public health priority. WHO Press, Geneva, Switzerland.
94. Wu Z.L., Ciallella J.R., Flood D.G., O'Kane T.M., Bozyczko-Coyne D., Savage M.J. Comparative analysis of cortical gene expression in mouse models of Alzheimer's disease. Neurobiol. Aging 2006, 27:377-386.
95. Wyss-Coray T., Loike J.D., Brionne T.C., Lu E., Anankov R., Yan F., Silverstein S.C., Husemann J. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat. Med. 2003, 9:453-457.
96. Wyss-Coray T., Yan F., Lin A.H.T., Lambris J.D., Alexander J.J., Quigg R.J., Masliah E. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc. Natl. Acad. Sci. U. S. A 2002, 99:10837-10842.
97. Xu P.T., Li Y.J., Qin X.J., Scherzer C.R., Xu H., Schmechel D.E., Hulette C.M., Ervin J., Gullans S.R., Haines J., Pericak-Vance M.A., Gilbert J.R. Differences in apolipoprotein E3/3 and E4/4 allele-specific gene expression in hippocampus in Alzheimer disease. Neurobiol. Dis. 2006, 21:256-275.
98. Yan P., Bero A.W., Cirrito J.R., Xiao Q., Hu X., Wang Y., Gonzales E., Holtzman D.M., Lee J.M. Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J. Neurosci. 2009, 29:10706-10714.
99. Yao S., Wang S., Zhu Y., Luo L., Zhu G., Flies S., Xu H., Ruff W., Broadwater M., Choi I.H., Tamada K., Chen L. PD-1 on dendritic cells impedes innate immunity against bacterial infection. Blood 2009, 113:5811-5818.
100. Yu J.T., Mou S.M., Wang L.Z., Mao C.X., Tan L. Toll-like receptor 2 -196 to -174 del polymorphism influences the susceptibility of Han Chinese people to Alzheimer's disease. J. Neuroinflammation 2011, 8:136.
101. Zhang W., Bai M., Xi Y., Hao J., Zhang Z., Su C., Lei G., Miao J., Li Z. Multiple inflammatory pathways are involved in the development and progression of cognitive deficits in APPswe/PS1dE9 mice. Neurobiol. Aging 2012, 33:2661-2677.
102. Zota V., Nemirovsky A., Baron R., Fisher Y., Selkoe D.J., Altmann D.M., Weiner H.L., Monsonego A. HLA-DR alleles in amyloid beta-peptide autoimmunity: a highly immunogenic role for the DRB1*1501 allele. J. Immunol. 2009, 183:3522-3530.